Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial

Guillermo de Velasco; Lucia Carril-Ajuria; Felix Guerrero-Ramos; Teresa Alonso-Gordoa; Juan F. Rodríguez-Moreno; Alberto Carretero; Maricruz Martin-Soberon; Federico de la Rosa-Kehrmann; Daniel Castellano

doi:10.18632/oncotarget.28263

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial

PDF | How to cite

Oncotarget. 2022; 13:983-983. https://doi.org/10.18632/oncotarget.28263

Metrics: PDF 635 views | ?

Guillermo de Velasco¹, Lucia Carril-Ajuria¹, Felix Guerrero-Ramos², Teresa Alonso-Gordoa³, Juan F. Rodríguez-Moreno⁴, Alberto Carretero¹, Maricruz Martin-Soberon¹, Federico de la Rosa-Kehrmann² and Daniel Castellano¹

¹Medical Oncology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain
²Urology Department, Hospital Universitario 12 de Octubre, Comunidad de Madrid, Madrid, Spain
³Medical Oncology Department, Hospital Universitario Ramón y Cajal, Comunidad de Madrid, Madrid, Spain
⁴Medical Oncology Department, Hospital Universitario HM Sanchinarro, Comunidad de Madrid, Madrid, Spain

Published: August 04, 2022

Copyright: © 2022 de Velasco et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: All patients signed informed consent.

Original article: Oncotarget. 2020; 11:4457–4462. DOI: https://doi.org/10.18632/oncotarget.27807

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28263

Publication Alerts

Addendum:

Addendum: A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial